S-1/A: First Choice Healthcare Pivots to Wellness, Seeks $19M IPO

First Choice Healthcare Solutions, Inc. is undergoing a major strategic shift from orthopedics to a national chain of primary care and wellness clinics, aiming to raise up to $19 million in a public offering.

Summary

• First Choice Healthcare Solutions, Inc. (FCHS) is transitioning its business strategy from orthopedic services to developing a national chain of primary care and wellness clinics, focusing on anti-aging, weight management, and hormone replacement services.
• The company plans to terminate all remaining legacy orthopedic and physical therapy services upon the closing of the public offering.
• FCHS has entered into agreements to acquire Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC (collectively 'Pointe Med Pharmacy') for $15,800,000, payable in cash, debt assumption, stock, earn-out, and bonus.
• An asset purchase agreement was also signed to acquire The Good Clinic, Inc.'s physical and intangible assets for $3,500,000 in an all-stock deal.
• The company is conducting a 'best efforts' public offering of up to 3,800,000 shares of Series D Convertible Preferred Stock and warrants to purchase an equal number of Series D Convertible Preferred Stock shares, with an assumed initial conversion and exercise price of $5 per share.
• A minimum of $15.0 million must be raised in the public offering for the offering, acquisitions, and exchange of notes/liabilities to close.
• Net proceeds from the offering are expected to be $17,080,000 (or $19,702,000 if the over-allotment option is fully exercised), allocated primarily to acquisitions ($9,000,000), hiring key personnel ($2,000,000), working capital ($4,580,000), and marketing ($1,500,000).
• A 1 for 2,000 reverse stock split of the common stock outstanding as of March 27, 2026, was approved by the Board of Directors on September 15, 2024, to be effective prior to NYSE listing, but it will not apply to shares issued in the IPO, resale shares, or acquisition-related shares.
• Selling stockholders are offering up to 3,000,010 shares of common stock for resale, including 51,114 shares from warrant exercises, which are not subject to the reverse stock split.
• FCHS reported net losses of approximately $7.0 million in 2025 and $3.9 million in 2024, with accumulated deficits of $74.7 million and $67.8 million, respectively.
• Pointe Med/LiveWell, the acquired entity, reported net income attributable to shareholders of $597,525 in 2025 and $1,414,493 in 2024, with revenues of $6,963,877 and $5,649,346, respectively.
• The company's ability to continue as a going concern is dependent on successful acquisitions, revenue growth, cost reduction, and securing additional capital.
• Lance Friedman, CEO, currently holds all 4 shares of Series A Super Voting Preferred Stock, which will be cancelled upon completion of the offering, eliminating his effective voting control.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly speculative investment due to the company's significant historical losses, accumulated deficit, and explicit 'going concern' warning. While the strategic pivot and acquired entities show promise, the success is contingent on a successful capital raise and execution of a new, unproven business model for FCHS, making it a high-risk proposition.

Positives

• The strategic pivot to primary care and wellness clinics, including anti-aging, weight management, and hormone replacement, targets high-growth markets and aims to redefine primary care.
• The acquisitions of Pointe Med Pharmacy and The Good Clinic provide established operations and intellectual property (e.g., 'The Good Clinic' trademark) to support the new strategy.
• Pointe Med/LiveWell, the acquired entity, demonstrated positive net income of $597,525 in 2025 and $1,414,493 in 2024, and increased revenue by 23% to $6,963,877 in 2025, indicating a profitable core for the new business model.
• The use of Nurse Practitioners as primary healthcare professionals is expected to provide a 25% labor cost advantage over traditional physician-staffed offices, improving profit margins.
• The company plans to leverage a centralized administrative infrastructure to achieve economies of scale in billing, collections, purchasing, advertising, and compliance, reducing expenses and fueling income growth.
• The acquired LiveWell Drugstore compounding pharmacy offers sterile and nonsterile formulations, enabling personalized prescription medication and potential expansion into non-patient specific medications (503B status) for broader supply.
• The EMR system is cloud-based and complies with Meaningful Use standards, enhancing patient information access and reducing hazards from disparate healthcare systems.
• The company has identified new, experienced board members, including Barbara J. Sher (President & COO), Joseph Clemente (CFO), Gary E. Stein, James Hennig, and Mara Jacobs, to strengthen governance and operational expertise.
• The cancellation of the Series A Super Voting Preferred Stock held by the CEO upon offering completion will dilute his voting control, potentially improving corporate governance and shareholder democracy.

Negatives

• First Choice Healthcare Solutions, Inc. (FCHS) has a history of minimal profit, posting net losses of $7.0 million in 2025 and $3.9 million in 2024, and recurring cash outflows from operations.
• The company has an accumulated deficit of $74.7 million as of December 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• The success of the strategic pivot and continued operations is highly dependent on raising additional capital, which may not be available on favorable terms or at all.
• The company's indebtedness amounted to $43,575,506 as of December 31, 2025, which could require a substantial portion of cash flows for debt service.
• The former CEO, Christian C. Romandetti, Sr., pled guilty to conspiracy to commit securities fraud, which has tarnished the company's reputation and led to litigation.
• The company faces significant risks in integrating the acquired businesses (Pointe Med Pharmacy and The Good Clinic) and managing growth in multiple new markets.
• The quality of life services, projected to be 15% of clinic revenue, will be primarily self-pay, leading to potential revenue volatility, bad debt risk, and pricing challenges.
• The anti-dilution provisions in the Series D Convertible Preferred Stock could lead to an indeterminate number of common shares being issued, causing substantial dilution to existing stockholders.
• There is no established public trading market for the Offered Preferred Stock or the Warrants, and the company does not expect one to develop, limiting liquidity.
• The company has broad discretion in the use of net proceeds from the offering, which may not be used effectively, particularly if acquisitions are unsuccessful.
• The company has not paid dividends in the past and has no immediate plans to do so, meaning investors should not expect cash dividends.

Risks

• Our business has posted minimal profit since commencing operations, with net losses of approximately $7.0 million in 2025 and $3.9 million in 2024, and accumulated deficits of $74.7 million and $67.8 million, respectively.
• If our cash from operations is not sufficient to meet our current or future operating needs, expenditures and debt service obligations, our business, financial condition, and results of operations may be materially adversely affected.
• We need additional capital to expand operations; if we do not raise additional capital, we will need to curtail or cease operations.
• Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or other assets.
• Our strategy to open new clinics sites in multiple new markets makes it difficult for us to evaluate our current and future business prospects, and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment and could harm our business, financial condition, results of operations and cash flow.
• Changes in tax laws and unanticipated tax liabilities could adversely affect our effective income tax rate and ability to achieve profitability.
• We expect our quarterly financial results to fluctuate.
• Volatility in the financial markets could have a material adverse effect on our business.
• Potential profit margins may decline due to increasing pressure on margins.
• Our indebtedness may have a material adverse effect on our business, financial condition, and results of operations.
• Pandemics and epidemics, including the COVID-19 pandemic, natural disasters, terrorist activities, political unrest, and other outbreaks could have a material adverse impact on our business, results of operations, financial condition and cash flows or liquidity.
• Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of our clinic operations and adversely impact our business.
• We have a limited operating history that impedes our ability to evaluate our potential future performance and strategy.
• Acquisitions involve risks that could adversely affect our business/internal controls.
• We may not be able to achieve the expected benefits from opening new primary care clinics, which would adversely affect our financial condition and results.
• If we are unable to attract and retain qualified medical professionals, our ability to maintain operations attract patients or open new primary care clinics could be negatively affected.
• We may have difficulties managing our Company's growth, which could lead to higher operating losses, or we may not grow at all.
• Loss of key executives and failure to attract qualified managers could limit our growth and negatively impact our operations.
• We may be subject to medical professional liability risks, which could be costly and could negatively impact our business and financial results.
• The healthcare regulatory and political framework is evolving.
• The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws or regulations.
• The practice of pharmacy is highly regulated on the state and federal level, and government authorities may determine that we have failed to comply with applicable laws or regulations limiting our opportunity to grow our compounding pharmacy revenue.
• Compounding pharmacies are dependent on the consistent availability and quality of the base pharmaceuticals required to deliver personalized medications to their patients and clinics.
• Federal and state laws that protect the privacy and security of protected health information may increase our costs and limit our ability to collect and use that information and subject us to penalties if we are unable to fully comply with such laws.
• Our primary clinics will be based primarily on the self-pay model, which could lead to lesser patients utilizing our services or the need for us to discount such services, which could limit our growth and negatively impact our operations.
• Changes in the rates or methods of third-party reimbursements for medical services could result in reduced demand for our services or create downward pricing pressure, which would result in a decline in our revenues and harm our financial position.
• We are subject to federal and state restrictions on advertising that may adversely affect our ability to advertise our clinics and services.
• Health Insurance Portability and Accountability Act (HIPAA) compliance is critically important to our continuing operations.
• We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
• The market for healthcare services is highly competitive.
• If we are forced to lower our procedure prices in order to compete with a better-financed or lower-cost provider of medical healthcare services, our medical revenues and results of operations could decline.
• A decline in consumer disposable income could adversely affect the number of clinical visits and could have a negative impact on our financial results.
• We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.
• The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we are no longer an emerging growth company.
• We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• There has been a limited trading market for our Common Stock to date.
• The market for our common stock may fluctuate significantly.
• A significant percentage of the Company's common stock is held by a small number of shareholders.
• The issuance of our common stock in connection with the Company's outstanding convertible preferred stock and warrants could cause substantial dilution, which could materially affect the trading price of our common stock.
• Resales by the selling stockholders under the Resale Prospectus may have an adverse effect on the market price of our Common Stock.
• We have not paid dividends in the past and have no immediate plans to pay dividends.
• We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline.
• Penny stock rules may make buying or selling our securities difficult which may make our stock less liquid and make it harder for investors to buy and sell our securities.
• Our former Chief Executive Officer, Christian C. Romandetti, Sr., was arrested on November 15, 2018, on a conspiracy to commit securities fraud charge.
• Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
• Failure to achieve and maintain internal controls in accordance with Sections 302 and 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.

Future Outlook

The company's future outlook is centered on a strategic pivot to a national chain of primary care and wellness clinics, with operations expected to commence by June 1, 2026. This strategy aims to leverage Nurse Practitioners for cost advantages and provide personalized care, including anti-aging, weight management, and hormone replacement services, supported by an internal compounding pharmacy. The company anticipates achieving economies of scale through centralized administrative functions as it expands its clinic network, with plans to open five clinics by December 2025 and a total of thirty new clinics in the next four years. Success is contingent on securing the necessary capital from the current offering and effective execution of the business plan amidst a highly competitive and regulated healthcare market.

Management Comments

• Management made the strategic decision to pivot away from the orthopedic services model to leveraging our management services infrastructure to support the development and growth of a national chain of branded primary care and wellness clinics following our exit from bankruptcy.
• We expect to be able to commence operations for the primary care and wellness clinics as part of our new strategy starting June 1, 2026.
• We are confident in the market size of our business opportunity, the strength of our strategy, and the experience of our management team.
• We believe our strategy of combining a full suite of primary care services and the specialized services of our competition in an operational environment focused on providing high quality care, excellent customer experience, personalized care plans and personalized medications will deliver our desired financial performance.
• It is our plan that the cost of our back-office operations will not increase in direct relation to the growth of our network of primary care clinics, which will allow us to sustain profit margins across our business operations with a cost effective and scalable back office.
• The Company believes that it will be successful in repairing its relationships with employees and referral sources, generating growth and improved profitability resulting in improved cash flows from operations.

Industry Context

StockSavvy.ai notes that First Choice Healthcare Solutions' pivot towards primary care and wellness clinics aligns with broader industry trends emphasizing preventive care, personalized medicine, and cost-effective delivery models. The focus on Nurse Practitioners leverages a growing segment of the healthcare workforce known for providing quality care at lower costs, a strategy also seen in competitors like MinuteClinic and certain digital health platforms. The integration of compounding pharmacies and self-pay quality-of-life services positions the company to capture market share in the expanding anti-aging, weight management, and hormone replacement sectors, which are experiencing significant growth (e.g., pharmaceutical weight loss market projected to reach $100 billion by 2030, HRT market to $13.4 billion by 2032). However, the fragmented and competitive nature of the healthcare market, with established virtual and brick-and-mortar players, presents significant challenges for differentiation and patient acquisition.

Comparison to Industry Standards

• The company's strategy to utilize Nurse Practitioners for primary care is noted to provide an approximate 25% margin improvement over traditional primary care offices staffed with medical doctors, aligning with studies suggesting Nurse Practitioners deliver care equal to or better than physicians.
• The U.S. primary care market was valued at $271.0 billion in 2023 and is expected to grow at a CAGR of 3.36% from 2024 to 2030, indicating a substantial market opportunity for the company's new strategy.
• The pharmaceutical weight loss market, valued at $6 billion in 2023, is projected to grow to $100 billion by 2030 (Goldman Sachs Research), positioning the company's medically assisted weight management services in a high-growth segment.
• The Hormone Replacement Therapy (HRT) market, valued at $6.9 billion in 2022, is expected to reach $13.4 billion by 2032 (Global Market Insights), suggesting strong demand for the company's HRT offerings.
• The U.S. peptides market, valued at $17.8 billion in 2022, is projected to grow at a CAGR of 7.0% from 2023 to 2030 (Global Market Insights), indicating a growing market for peptide-based therapies the company plans to offer.
• The U.S. regenerative medicine market, estimated at $16.8 billion in 2023, is projected to grow at a CAGR of 16.72% from 2024 to 2030 (Grand View Research), highlighting the high-growth potential of the company's planned regenerative therapies.
• The biohacking market, estimated at $23.9 billion in 2023, is projected to grow at a CAGR of 19.48% to $67.9 billion by 2032 (Market Research Future), indicating a rapidly expanding niche for the company's biohacking programs.
• The company faces competition from virtual competitors (e.g., Hims, Ro, REX MD, Renew Youth, Alloy, Midi), brick-and-mortar clinics (e.g., Revibe, Herself Health, Oak Street Medical, One Medical), and individual private practices, many of which may have greater name recognition, longer operating histories, and significantly greater financial resources.

Management Changes

Corporate Governance

Legal Proceedings

• The former Chief Executive Officer, Christian C. Romandetti, Sr., pled guilty to conspiracy to commit securities fraud, which has negatively impacted the company's reputation and led to litigation.
• The company filed for Chapter 11 bankruptcy on June 15, 2020, and emerged on April 27, 2022, which settled or converted all litigation into unsecured creditors.
• An equipment lease judgment for $19,473 was granted against the company on January 25, 2024, which was subsequently settled for $9,000 in March 2024.
• GMR Melbourne, LLC filed a complaint for breach of contract related to a facilities lease agreement, claiming $1,455,095, with approximately $1,200,000 remaining as an open accounts payable liability as of December 31, 2024.
• Coastal Neurology, Inc. filed a complaint for breach of contract for $100,000 on May 11, 2023, but subsequently withdrew the complaint in 2024.
• CBL & Associates Properties, Inc. is seeking $84,051 for defaulted lease payments and collection costs, which the company has accrued.
• MBABJB Holdings Family Limited Partnership was granted a summary judgment for $102,884 (including attorney fees and costs) for defaulted lease payments, which the company has accrued.
• Ackerman, LLP was awarded $548,000 in fees for bankruptcy representation, and after defaulting on a payment plan, a summary judgment was granted, with $203,115 of these legal fees remaining unpaid.
• The company is a defendant in several employment-related matters, primarily for unpaid wages following staff reductions, with most cases settled and paid, except for one $10,000 judgment not yet disbursed.

Related Party Transactions

• As of December 31, 2025, $1,153,846 of Other Non-Convertible Notes were due to Thor Special Situations LLC, a related party to the company's Chief Executive Officer, Lance Friedman.
• As of December 31, 2024, $1,626,983 of Other Non-Convertible Notes were due to the company's Chief Executive Officer, Lance Friedman, related to deferred compensation and third-party service payments, which was reduced by payments and exchanges in 2025.
• A lease agreement dated October 1, 2019, for space is with Live Well Realty, LLC, a related party, expiring on June 30, 2028.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the public offering and potential future conversions of Series D Preferred Stock and warrants, especially given the anti-dilution provisions. Existing shareholders who participated in the private placement will have their shares excluded from the reverse split, offering some protection. The cancellation of Series A Super Voting Preferred Stock will increase the voting power of common shareholders.
• Employees: The strategic pivot involves terminating legacy orthopedic and physical therapy services, which may lead to job losses in those areas, but also new hiring for primary care and wellness clinics, including Nurse Practitioners and administrative staff.
• Customers/Patients: The new strategy aims to provide a 'more effective medical home' with personalized care, a broad spectrum of services, and an internal compounding pharmacy, potentially leading to improved patient experience and outcomes. However, the reliance on a self-pay model for 'quality of life' services may limit access for some patients.
• Creditors: The public offering proceeds are crucial for settling existing notes payable and other liabilities, including SBA loans and lease obligations, which could improve the company's financial stability and reduce creditor risk.
• Regulatory Authorities: The company operates in a highly regulated healthcare and pharmacy environment, requiring strict compliance with federal and state laws (e.g., HIPAA, anti-kickback, false claims). Any non-compliance could result in penalties, fines, or exclusion from government programs.

Next Steps

• Complete the public offering of Series D Convertible Preferred Stock and Warrants, raising at least $15.0 million.
• Close the acquisitions of Pointe Med Pharmacy entities and The Good Clinic, Inc. immediately after the offering closes.
• Complete the contemplated 1 for 2,000 reverse stock split immediately after the effectiveness of the Registration Statement but prior to NYSE listing.
• Apply to list common stock on the NYSE under the symbol FCHS (or 'Leading Primary Care, Inc.' after proposed name change).
• Commence operations for the primary care and wellness clinics as part of the new strategy starting June 1, 2026.
• Re-establish the Audit, Compensation, and Nominating and Governance committees of the Board of Directors in the third quarter of 2025.
• Increase the number of state licensures for LiveWell Drugstore to include each state where primary care clinics operate.
• Pursue FDA approval for LiveWell Drugstore to become an FDA-registered 503B pharmacy.
• Expand the network of primary care clinics, with a plan to open five clinics by December 2025 and a total of thirty new clinics in the next four years.
• Evaluate Denver and Phoenix markets for potential future expansion opportunities.

Key Dates

Recommendation

First Choice Healthcare Solutions is undergoing a transformative strategic pivot and a critical capital raise. While the historical financial performance of FCHS is poor, with significant losses and a going concern warning, the acquired entities (Pointe Med/LiveWell) demonstrate profitability and align with a high-growth market strategy. The success of this offering and the subsequent execution of the new business model are highly speculative. Investors should 'hold' existing positions with extreme caution, awaiting clear evidence of successful integration, sustained profitability from the new clinics, and effective management of the substantial debt and regulatory risks. New investment is not recommended given the high degree of risk and uncertainty surrounding the company's ability to execute its ambitious plan and achieve financial stability.

Keywords

Healthcare, Primary Care, Wellness Clinics, Compounding Pharmacy, IPO, Series D Preferred Stock, Warrants, Reverse Stock Split, SEC Filing, Medical Services, Anti-aging, Weight Management, Hormone Replacement Therapy, Nurse Practitioners, Accredited Investor, Going Concern, Dilution, NYSE Listing